ASTRO ROCKS: 2022 ASTRO-Myovant Sciences-Pfizer Alliance New Combination (Relugolix-Radiation) Therapy Challenge
Under the ASTRO Advancing-Medicine-Together Scientific Challenges framework, the Myovant Sciences-Pfizer Alliance and ASTRO are partnering to host the 2022 New Combination (Relugolix-Radiation) Therapy Challenge to catalyze new collaborative research opportunities, and to facilitate radiation oncology leadership in scientific discovery with the Myovant Sciences-Pfizer Alliance in the space of multimodality combination therapy. In this informational webinar, representatives from the Myovant Sciences-Pfizer Alliance and ASTRO will focus on answering questions from any researchers who are interested in submitting their proposals about:
- The intent of this challenge and potential medical impact
- The Pfizer ISR Grant System for proposal submission
- Any other general program administration-related topics
Grant Agreement Requirements:
If your entry is recommended by the ASTRO Challenge Judging Panel, your institution will be required to enter into a written grant agreement with Pfizer and Myovant in order that support can be provided. Please click here to view the core terms of the agreement (though note that this is not the complete contract template). Neither Pfizer nor Myovant have the resources to negotiate grant agreements, so please ensure that your institution is able and willing to abide by these terms before proceeding with your application.
Updated Frequently Asked Questions (FAQ) can be accessed here for review.
This activity is available from June 2, 2022, through 11:59 p.m. Eastern time on June 1, 2025.
Researchers who are interested in submitting their proposals to be considered under the 2022 ASTRO-Myovant Sciences-Pfizer Alliance New Combination (Relugolix-Radiation) Therapy Challenge.
- H. Timothy Hsiao, PhD (Director, Department of Scientific Affairs, ASTRO)
- Paul L. Nguyen, MD (Professor, Harvard Medical School; Vice-Chair for Clinical Research & Director of Genitourinary Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center; ASTRO Member; Lead, Challenge Scientific Advisory Team)
- J. Christopher Spell, PhD (Director, Medical Affairs Strategy, Myovant Sciences)
- Jennifer Spear Smith, PhD (Director, Medical Education & Programs, Myovant Sciences)
- Dewayne Brumlow (Director, Oncology Grant Officer, Global Medical Grants, Pfizer)
- Traci Faughnan (Senior Manager, Global Medical Grants, Pfizer)
Questions can be directed to Science@ASTRO.org.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintence of Certification.
- 1.00 Certificate of AttendanceThis activity was designated for 0.00 AMA PRA Category 1 Credit™.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.